Clinical Trials Logo

Overactive Bladder (OAB) clinical trials

View clinical trials related to Overactive Bladder (OAB).

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05211193 Completed - Clinical trials for Overactive Bladder (OAB)

Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB).

Start date: January 8, 2020
Phase:
Study type: Observational [Patient Registry]

Open label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous NeuroModulation (eTNM) Treatment Via Nerve Stimulator URIS I in the Treatment of Overactive Bladder.

NCT ID: NCT04562090 Completed - Urge Incontinence Clinical Trials

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Start date: January 6, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants. This study also evaluated the safety of mirabegron for the treatment of OAB in Chinese participants, evaluated other efficacy variables of mirabegron for the treatment of OAB and explored different mirabegron starting doses.

NCT ID: NCT03903094 Completed - Clinical trials for Overactive Bladder (OAB)

A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden

Start date: March 7, 2019
Phase:
Study type: Observational

Outpatients with at least one dispensing record of any medication will be included in the study. An index date will be assigned to each participant and prescription records for anticholinergics will be used in the study.

NCT ID: NCT03846895 Completed - Clinical trials for Overactive Bladder (OAB)

Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB)

Start date: May 12, 2018
Phase: N/A
Study type: Interventional

This study evaluates the clinical efficacy and symptom relief of vaginal fractional CO2 laser treatment in post-menopausal women with Overactive Bladder syndrome(OAB). Post-menopausal women with OAB syndrome who receive β3 adrenergic receptors (mirabegron 50mg) treatment, will be randomized in two groups. Half participants will receive active CO2 laser therapy, while the other half will receive placebo CO2 laser therapy.

NCT ID: NCT03602508 Completed - Clinical trials for Overactive Bladder (OAB)

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Start date: July 20, 2018
Phase:
Study type: Observational

The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan. This study will also assess the persistence to the overall Overactive bladder (OAB) treatments of a patient, regardless of treatment discontinuation or switch to other OAB medications.

NCT ID: NCT03572231 Completed - Clinical trials for Overactive Bladder (OAB)

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Start date: July 19, 2018
Phase:
Study type: Observational

The purpose of this study is to observe and describe treatment patterns, like Overactive Bladder (OAB) treatment discontinuation, switching to other therapies and persistence of OAB therapies in routine clinical practice. This study will also evaluate effectiveness of OAB therapies in routine clinical practice; identify factors associated with effectiveness and persistence of pharmacologic therapies in OAB participants; evaluate the Quality of Life (QoL) and treatment satisfaction of OAB therapies; as well as evaluate health care resource utilization (HCRU) and understand adverse events (AEs), serious adverse events (SAEs) and adverse drug reactions (ADRs) associated with OAB therapies.

NCT ID: NCT02294396 Completed - Clinical trials for Overactive Bladder (OAB)

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

Start date: October 28, 2014
Phase: Phase 4
Study type: Interventional

The objective of the study was to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with OAB on mirabegron.

NCT ID: NCT02216214 Completed - Clinical trials for Overactive Bladder (OAB)

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

PILLAR
Start date: October 7, 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.

NCT ID: NCT02138747 Completed - Clinical trials for Overactive Bladder (OAB)

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

PREFER
Start date: July 24, 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study was to assess tolerability of mirabegron compared to tolterodine ER in the treatment of participants with symptoms of Overactive Bladder (OAB) as well as the impact of treatment on micturition frequency and incontinence episodes.

NCT ID: NCT01936870 Completed - Clinical trials for Overactive Bladder (OAB)

Drug Use Investigation for Toviaz

Start date: October 1, 2013
Phase:
Study type: Observational

The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.